New research finds drug for alcohol use disorder ineffective

February 26, 2018, University of Liverpool
New research finds drug for alcohol use disorder ineffective
Credit: University of Liverpool

A new study, published in the Addiction journal, conducted by researchers from the University of Liverpool highlights the ineffectiveness of a specific drug treatment for alcohol use disorders.

Baclofen is a medication which has been used since the 1970s as an anti-spasticity treatment. More recently it has been used as a treatment for alcohol use disorders.

Baclofen has a key advantage compared with currently licensed medications: it is excreted largely through the kidneys. It is therefore possible to give to people suffering alcohol-related liver disease, a patient population with very high needs, and who often can't tolerate licensed drug treatments.

'Wonder drug'

Many studies have found baclofen to be successful in treating alcohol use disorders, some have claimed it a wonder drug capable of curing alcoholism.

Following a number of successful the use of use of baclofen increased massively and sales of the drug have soared in some countries.

In more recent years, there have been a growing number of studies which directly compare baclofen against placebo on a number of outcome measures. Often these outcome measures are drink-related, e.g. rate of abstinence at the end of the medication trial, or number of or abstinent days during the trial.

However, there are other measures, potentially related to why baclofen might work (i.e. its mechanism of action). Several possibilities have been identified; firstly baclofen may reduce craving for alcohol, secondly there are reports that baclofen reduces negative mood states, such as anxiety and depression, which are known risk factors for harmful drinking.

Abstinent rates

Researchers, Dr. Abi Rose and Dr. Andy Jones, from the University's Addiction Research Team conducted a meta-analysis on 12 clinical trials comparing baclofen with placebo on at least one of the described drinking outcomes, craving, anxiety, or depression.

Meta-analysis is an advanced statistical procedure that allows the researcher to merge the results of all the studies regarding a specific topic into a quantitative measure representing the size of the overall effect of one variable on another variable. Thus, meta-analysis provides more accurate and reliable outcomes compared to the single experiment.

The researchers found that baclofen led to higher abstinent rates compared with placebo, and that eight individuals would need to be treated with baclofen for one to remain abstinent due to the medication.

However, all other outcomes failed to show an effect of baclofen: baclofen did not increase abstinent days or decrease number of heavy drinking days during treatment, neither did it reduce rates of craving, anxiety or depression.

Issues highlighted

Dr. Rose, said: "Our research highlights several issues with the existing body of trials. Many of the studies only recruited a limited number of patients, so maybe too small to find an effect.

"The existing trials also differ on a number of factors, such as the dose of baclofen given and the length of treatment. Importantly, the pharmacokinetics of baclofen (how it moves in the body) are not well-understood, so there may be individual factors influencing the effectiveness of baclofen that we do not yet understand."

Dr. Jones, said: "This new meta-analysis shows that baclofen is no more effective than placebo on a range of key outcome measures, suggesting that the current increasing use of baclofen as a treatment for is premature."

Explore further: Study suggests prescribing of baclofen for alcohol dependence 'should be reconsidered'

More information: Abigail K. Rose et al. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis, Addiction (2018). DOI: 10.1111/add.14191

Related Stories

Study suggests prescribing of baclofen for alcohol dependence 'should be reconsidered'

November 30, 2016
The drug baclofen has received high visibility as a possible breakthrough treatment for alcohol dependence. Now a new randomised controlled trial from the University of Amsterdam found no evidence for the usefulness of high-dose ...

Drug used for alcohol dependence might also treat stuttering, suggest researchers

May 11, 2017
Baclofen, a drug that has recently been used to treat alcohol dependence despite not officially being licensed for this condition, might also help stop stuttering, suggest researchers in the journal BMJ Case Reports.

Baclofen shows promise in patients with alcohol-induced liver disease

April 23, 2015
Results revealed today at The International Liver Congress 2015, show that in patients with alcohol-induced liver disease (ALD), Baclofen has a positive impact on alcohol consumption and overall measures of liver function ...

Drug against alcoholism works, researchers claim

March 17, 2017
French researchers provided fresh evidence Friday to support claims that a drug touted as a miracle cure for alcoholism, and prescribed for this purpose in France, actually works.

No magic pill to cure alcohol dependence yet

September 21, 2017
A new study published by the scientific journal Addiction has found no reliable evidence for using nalmefene, naltrexone, acamprosate, baclofen or topiramate to control drinking in patients with alcohol dependence or alcohol ...

'Anti-alcoholism' drug cleared for use in France

April 25, 2012
French health authorities have approved the use of a drug, originally designed to treat nervous spasms, for the treatment of alcoholism on a "case by case" basis.

Recommended for you

Exercise helps treat addiction by altering brain's dopamine system

May 28, 2018
New research by the University at Buffalo Research Institute on Addictions has identified a key mechanism in how aerobic exercise can help impact the brain in ways that may support treatment—and even prevention strategies—for ...

Warning labels on alcohol containers highly deficient, new research shows

May 21, 2018
Current health warning labels on alcohol beverage containers in New Zealand are highly deficient, new research from the University of Otago, Wellington shows.

Serving smaller alcoholic drinks could reduce the U.K.'s alcohol consumption

May 14, 2018
New research published in Addiction, conducted by researchers from the Universities of Liverpool and Sheffield, highlights the potential benefits of reducing the standard serving size of alcoholic beverages.

Anti-alcoholism drug shows promise in animal models

May 3, 2018
Scientists at The University of Texas at Austin have successfully tested in animals a drug that, they say, may one day help block the withdrawal symptoms and cravings that incessantly coax people with alcoholism to drink. ...

FDA-approved drugs to treat diabetes and obesity may reduce cocaine relapse and help addicted people break the habit

April 28, 2018
Cocaine and other drugs of abuse hijack the natural reward circuits in the brain. In part, that's why it's so hard to quit using these substances. Moreover, relapse rates hover between 40 and 60 percent, similar to rates ...

Buprenorphine may be safer than methadone if treatment duration is longer, study suggests

April 20, 2018
The less commonly prescribed opioid substitute buprenorphine may be safer than methadone for problem opioid users, especially if used during the first month of treatment, according to a study which includes University of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.